Stapokibart Injection Observational Study, Atopic Dermatitis, Apr 22
ClinicalTrials.gov Studies
Summary
This study is an open-label, prospective observational study registered on ClinicalTrials.gov under NCT07544862 to evaluate the safety and efficacy of Stapokibart Injection in patients with Atopic Dermatitis (AD). The study was registered in April 2026 and lists Atopic Dermatitis as the condition and Stapokibart as the intervention. This is a standard clinical trial registry entry providing public transparency about ongoing research.
“This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 588 changes logged to date.
What changed
This document is a clinical trial registration entry for NCT07544862, an open-label observational study of Stapokibart Injection in patients with Atopic Dermatitis. The registry entry provides the study type, condition, and intervention but does not contain regulatory requirements or compliance obligations. Stakeholders monitoring the Stapokibart development program for atopic dermatitis may use this registration to track study status and identify potential sites of interest.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
Observational NCT07544862 Kind: OBSERVATIONAL Apr 22, 2026
Abstract
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Conditions: Atopic Dermatitis (AD)
Interventions: Stapokibart
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.